GlassScriptPhysician profile
Sabrina M Foskey
NPI 1497748446
$7,801.91
in general payments reported to CMS, 2019-2025
36 companies · $1,521 in 2025
The $1,521 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,092 · 2022: $970 · 2023: $1,933 · 2024: $2,286 · 2025: $1,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,671 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,671.16 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,801.44 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $924.06 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $608.60 | 2024-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $503.62 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $385.50 | 2023-2024 | Repatha, Otezla, Tepezza |
| Astellas Pharma US INC | $346.24 | 2023-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.82 | 2021-2024 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $250.00 | 2023-2024 | Austedo Xr |
| Pfizer INC. | $241.87 | 2021-2025 | |
| Gilead Sciences, INC. | $199.42 | 2023-2024 | Descovy, Vemlidy |
| Merck Sharp & Dohme LLC | $197.97 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $184.87 | 2023-2025 | |
| Glaxosmithkline, LLC. | $173.11 | 2021-2023 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $171.08 | 2021-2023 | |
| Mannkind Corporation | $151.09 | 2022-2023 | Afrezza |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $136.27 | 2025 | Rezdiffra |
| Dexcom, INC. | $125.00 | 2023 | Dexcom G7 Gss (161) |
| Otsuka America Pharmaceutical, INC. | $124.69 | 2024 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $120.20 | 2023 | Rexulti |
| Mylan Specialty L.P. | $115.66 | 2023 | Yupelri |
| Amarin Pharma, INC. | $110.15 | 2021-2022 | |
| Genentech USA, INC. | $102.40 | 2021 | |
| Exact Sciences Corporation | $73.58 | 2024-2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $68.50 | 2021-2022 | |
| Medtronic, INC. | $61.54 | 2021 | |
| Progenics Pharmaceuticals, INC. | $50.00 | 2024 | |
| Biogen, INC. | $48.99 | 2025 | Spinraza |
| Esperion Therapeutics, INC. | $32.84 | 2021-2024 | Nexletol |
| Phathom Pharmaceuticals, INC. | $29.24 | 2024 | Voquezna |
| Ardelyx, INC. | $27.86 | 2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $26.81 | 2024 | Dupixent |
| Renalytix Ai, INC. | $24.90 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Phadia US INC. | $21.86 | 2024 | Immunocap |
| Shield Therapeutics INC | $21.66 | 2023 | Accrufer |
| Janssen Pharmaceuticals, INC | $14.35 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabrina Foskey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.